Introduction {#s02}
============

EBV is one of eight human herpesviruses that establish life-long persistent infection in humans. It is estimated that \>90% of the global population are seropositive. It was the first described oncogenic virus, and to date, seven different malignancies are associated with EBV infection. Although primary infection in childhood is generally asymptomatic, acquisition in healthy adolescents can cause infectious mononucleosis (IM). In addition, EBV can induce lymphoproliferation, lymphoma, and hemophagocytic lymphohistiocytosis (HLH) in immunocompromised patients, suggesting continuous immune surveillance is critical for virus--host homeostasis ([@bib129]; [@bib47]; [@bib94]; [@bib26]; [@bib119]).

EBV virology, infection, and immunology {#s03}
=======================================

Although EBV is initially transmitted through saliva, the early events of infection are poorly understood. During primary infection, there is a high degree of viral shedding from the throat. However, the cellular source of these infectious virions remains contentious. Circumstantial evidence implicates oral epithelial cells and possibly some infiltrating B cells at mucosal surfaces as sites for primary viral replication. A possible role for oral epithelial cells gained momentum when full lytic virus replication was observed in lingual epithelium from patients coinfected with HIV ([@bib50]). However, subsequent studies of postmortem biopsies of normal lingual tissues indicated that such replication was infrequent ([@bib42]; [@bib34]). Similarly, whether B cells are required for initial viral infection and the mode of viral entry into B cells remain unclear. Nevertheless, viral glycoproteins (gp's) facilitate entry and internalization of EBV into host cells: gp350 initiates binding to B cells through interactions with the complement receptor CD21, and fusion with the cell membrane and internalization are triggered by gp42 binding MHC class II and then mediated by the core fusion complex gH/gL/gp42. As epithelial cells lack both MHC class II and CD21, the mechanisms by which EBV infects epithelial cells is distinct from B cells but appears to involve interactions between viral gH and several αV integrins (see [@bib129]; [@bib56]; [@bib47]; [@bib105]; [@bib94]; [@bib26]; [@bib119]; [@bib50]).

Binding of EBV to B cells may also facilitate formation of B cell--epithelial cell conjugates, which allows epithelial cell entry ([@bib56]; [@bib105]). The replicative cycle that follows viral entry results in the sequential expression of \>80 lytic proteins involved in producing new viral particles and/or immune evasion. Among these, at least three early lytic proteins---BNLF2A, BILF1, and BGLF5---interfere with antigen (Ag) processing and presentation to CD8^+^ T cells. BZLF1, another immediate early lytic protein, down-regulates MHC class II, whereas some EBV micro-RNAs reduce expression of ligands for NK cell--activating receptors ([@bib98]). Together, these immune evasion proteins provide a window of opportunity for the virus to establish infection.

Then, EBV switches to latent infection of B cells, which is critical for colonization of the host. Several models have been proposed for how EBV persists as a latent infection in B cells, including selective infection of memory B cells ([@bib122]) or, alternatively, infection of naive or activated B cells which traverse through a germinal center reaction to become EBV^+^ memory B cells ([@bib55]). Irrespective of the exact mechanism, latency can take one of at least three forms. Initially, EBV establishes a growth-transforming latent infection of B cells where expression of the full array of latent proteins (EBV nuclear Ags \[EBNA\] 1, 2, 3A, 3B, 3C, and LP; latent membrane proteins \[LMPs\] 1 and 2) along with several small noncoding RNAs, various micro-RNAs, and EBV-encoded small RNAs can be detected. This is classed as latency III and is similar to that observed in EBV-transformed B cell lymphoblastoid cell lines (LCLs) in vitro. Among the latent proteins, LMP1 and LMP2 mimic signaling through CD40 and the B cell receptor, respectively. Consequently, latently infected B cells expand rapidly in extrafollicular areas of oropharyngeal lymphoid tissues such as the tonsils, and large numbers of infected B cells can be found in the blood. Most of these infected cells are cleared by the immune system; however, EBV then enters a more restricted form of latency to escape such immune control. In the latency II program, only EBNA1 and LMPs are expressed, whereas only EBNA1 is expressed in latency I. In fact, viral persistence is achieved largely through silent infection of memory B cells where expression of viral Ags is extinguished (latency 0); in healthy carriers, EBV is exclusively found within this population in the blood. These long-lived memory B cells are proposed to recirculate continuously between blood and oropharyngeal lymphoid tissues. Viral reactivation likely occurs when these cells enter oropharyngeal lymphoid tissues, resulting in viral replication at the barrier surface to seed foci of new infection and viral shedding ([Fig. 1](#fig1){ref-type="fig"}; [@bib55]; [@bib56]; [@bib47]; [@bib94]; [@bib26]; [@bib119]; [@bib122]).

![**EBV infection and viral persistence in the tonsils of immunocompetent hosts.** Early events of infection are poorly understood. However, there is accumulating evidence for a potential role for oral epithelial cells and/or infiltrating B cells. Orally transmitted virus is believed to establish lytic infection within the lymphoepithelium of the oropharynx, resulting in shedding of high levels of virus in the throat. Then, the virus switches to a growth-transforming latent infection (Lat III) of B cells within the local lymphoid tissues leading to proliferation of infected cells. However, viral persistence is largely achieved through the silent infection of memory B cells, where viral DNA is maintained in a circular form and no viral proteins are expressed. These virally infected memory B cells are believed to constantly recirculate between blood and oropharyngeal lymphoid tissues. Occasional reactivation of the virus within these lymphoid tissues may result in the production of new viral particles that could seed new foci of new infection of local B cells and also result in viral shedding from the throat. In immunocompetent hosts, tight immune control maintains virus during both lytic phase and latency. During primary infection as seen in IM, the vast array of antigenically rich EBV-lytic and -latent proteins induce priming and expansion of EBV-specific CD4^+^ and CD8^+^ T cells, as well as activation of NK cells. These effective immune responses bring the infection under control. Upon disease resolution, contraction of the T cell pool results in a small population of the memory T cell pool that persists both as tissue-resident memory cells (Trm cells) and circulating memory cells. Continuous immune surveillance by these resident and circulating memory cells is important for viral control. Black arrows denote movement of infected B cells.](JEM_20161846_Fig1){#fig1}

The clinical manifestations of primary EBV infection depend on the age and immunocompetent state of the host. In children, EBV is mostly acquired asymptomatically. However, 10% of infected adolescents develop IM, a febrile disease characterized by sore throat, swollen lymph nodes, body aches, and fatigue. Rare complications can lead to chronic active EBV infection, where severe symptoms persist for \>6 mo ([@bib29]; [@bib56]; [@bib47]; [@bib6]; [@bib94]; [@bib26]; [@bib119]).

Role of innate lymphocytes in EBV immunity {#s04}
------------------------------------------

Most data pertaining to the immunological events surrounding primary EBV infection is derived from studying IM patients. Innate immune responses, mediated by NK and NKT cells, may be involved during primary EBV acquisition. Studies have shown both direct and inverse correlations between NK cell frequencies, severity of symptoms, and EBV load in IM patients, suggesting NK cells may play a role in either protection against EBV infection or pathogenesis of IM ([@bib128]; [@bib6]). These disparate findings may reflect the dynamics of responses of specific subsets of NK cells during EBV infection ([@bib5]; [@bib22]).

Despite these opposing findings, numerous studies support a role for NK cells in anti-EBV immunity. NK cells can reduce EBV-mediated growth transformation of B cells ([@bib113]; [@bib5]; [@bib22]), probably because of their ability to be potently activated by EBV-induced ligands on infected B cells ([@bib58]). In vivo depletion of NK cells from humanized mice caused more severe symptoms and a greater incidence of EBV-induced tumorigenesis than in NK-sufficient hosts ([@bib21], [@bib22]). Thus, a failure of early viral control by NK cells could lead to IM. A role for NKT cells in immune-mediated control of EBV infection has also been posited, as these cells can limit EBV transformation of B cells in vitro ([@bib23]) and are absent from some individuals who are susceptible to EBV-induced disease ([@bib80]). The possible contributions of NK and NKT cells to host defense against EBV are discussed in The relative importance of innate versus adaptive immune cells in responses against EBV infection section.

Role of adaptive immunity in EBV immunity {#s05}
-----------------------------------------

Adaptive immunity is unequivocally required for robust anti-EBV immunity, as shown by severe EBV-induced disease in individuals with broad defects in T cell development or function ([@bib80]; [@bib90]; [@bib119]). During primary EBV infection in IM patients, the absolute number of peripheral blood CD8^+^ T cells increases 5--10-fold compared with asymptomatic individuals ([@bib18]; [@bib119]). The majority of activated CD8^+^ T cells are specific for lytic Ag, with responses to individual epitopes comprising up to 50% of the total CD8^+^ T cell pool, whereas responses to latent Ag are typically 10-fold lower in magnitude ([@bib18]; [@bib59]; [@bib63]; [@bib119]). Coinciding with the expansion of activated CD8^+^ T cells are elevated serum levels of proinflammatory and immunoregulatory cytokines (IFN-γ, TNF, IL-6, IL-10, and TGF-β; [@bib18]; [@bib83]). In comparison, there is a modest increase in proportions of EBV-specific CD8^+^ T cells in asymptomatic patients, accounting for up to 15% of all CD8^+^ T cells, contracting to ∼2--5% of memory CD8^+^ T cells upon viral control ([@bib47]).

EBV-specific CD4^+^ T cells can comprise up to 1% of all circulating CD4^+^ T cells in IM patients, contracting to ∼0.1% upon infection resolution ([@bib4]; [@bib64]). CD4^+^ T cell responses are directed toward a broader repertoire of viral Ags, with latent-specific responses dominating over lytic-specific responses; these cells not only secrete cytokines, but also can be cytotoxic ([@bib4]; [@bib63]; [@bib47]; [@bib75]; [@bib68]; [@bib94]; [@bib119]). These observations suggest that although numerically small, CD4^+^ T cell responses may also be important in controlling EBV infection ([@bib4]; [@bib64]). This is consistent with HIV/AIDS patients having low CD4^+^ T cell counts, high EBV viral loads, commonly developing EBV-associated lymphomas ([@bib89]; [@bib26]), and improved outcomes of adoptive T cell therapy for EBV-driven posttransplant lymphoproliferative disease (PTLD) when EBV-specific CD4^+^ T cells are transferred with CD8^+^ T cells ([@bib97]; [@bib41]).

Antibody (Ab)-mediated immune responses are typically required to successfully generate protective immunity against vaccines and many natural pathogen infections ([@bib117]). Patients with IM have lower levels of gp350-specific neutralizing Ab than healthy carriers ([@bib84]), and although vaccination of seronegative adults with a gp350 vaccine did not prevent EBV infection, symptoms of IM were reduced in these individuals ([@bib110]; [@bib26]). These findings suggest that although specific Abs are generated after EBV infection, these Abs may preferentially influence disease severity rather than prevent viral infection. This may be one explanation for the challenges in generating a successful and durable EBV vaccine ([@bib26]).

Primary immunodeficiencies (PIDs) reveal cell types and signaling pathways critical for host defense against EBV infection and disease {#s06}
======================================================================================================================================

PIDs are generally caused by monogenic mutations that compromise immune cell development, differentiation, or function. Consequently, affected individuals are highly susceptible to infection by a diverse array of pathogens. Whereas some immunodeficient individuals exhibit susceptibility to a broad range of bacterial, viral, and fungal infections, others are vulnerable to a surprisingly narrow range of pathogens ([@bib90]). Thus, the study of PIDs not only identifies genetic defects underlying infectious disease, but also provides mechanistic insight into nonredundant cellular, molecular, and biochemical pathways required for host defense against specific pathogens.

Several PIDs have been described in which chronic EBV viremia and/or EBV-induced disease (e.g., fulminant IM, HLH, lymphoproliferation, lymphoma, and dysgammaglobulinemia) are common features of the clinical presentation of affected individuals ([@bib86]; [@bib27]; [@bib80]). Studies of these patients have provided great insight into the functional requirements for efficacious immune responses against EBV. Although up to 18 different genetic mutations can predispose affected individuals to EBV-induced disease ([@bib86]; [@bib27]; [@bib80]), we will focus on those PIDs where EBV is predominantly responsible for the most severe clinical features of these conditions. We will also summarize recently described EBV-susceptible PIDs ([Table 1](#tbl1){ref-type="table"}).

###### Human PIDs manifesting as severe EBV-induced disease

  Mutated gene                   Clinical features                                                                                                                                                                                                                                                                                     Infections                                                    Outcomes                                                                                                                           References
  ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  *SH2D1A* (XLP-1); *n* \> 100   age of onset: 0.5--40 yr; EBV viremia (65%); severe FIM/HLH (∼50--60%); hypogammaglobulinemia (40--50%); B lymphoma (Burkitt's/NHL; often EBV^−^) ∼25%                                                                                                                                                EBV                                                           ∼30--75% mortality (depends on study in relation to discovery of *SH2D1A* gene mutation in 1998); successfully treated with HSCT   [@bib25]; [@bib73]; [@bib102]; [@bib115]; [@bib11]; [@bib79]; [@bib116]
  *XIAP* (XLP-2); *n* \> 100     age of onset: 0.5--40 yr; EBV viremia (50--60%); severe FIM/HLH (∼50--90%); splenomegaly/hepatitis (50--80%); inflammatory bowel disease (10--25%), cytopenias; transient hypogammaglobulinemia (10%)                                                                                                 EBV; CMV, HHV6                                                ∼40--80% mortality; poor outcomes after HSCT                                                                                       [@bib95]; [@bib33]; [@bib67]; [@bib79]; [@bib111]; [@bib2]
  *ITK*; *n* = 13                age of onset: 3--13 yr; EBV viremia (100%); EBV-induced lymphoproliferation (∼70%); EBV^+^ B cell lymphoma (mostly Hodgkin's; 1 NHL; 1 Burkitt's lymphoma; ∼70%); CD4^+^ T cell lymphopenia (∼65%); splenomegaly (∼60%); progressive hypogammaglobulinemia (\>50%); autoimmunity (infrequent; ∼20%)   EBV; CMV, VZV                                                 ∼60--65% mortality; 2/3 patients successfully treated with HSCT                                                                    [@bib49]; [@bib62]; [@bib66]; [@bib36]; [@bib8]; [@bib24]; [@bib17]
  *MAGT1*; (X-MEN) *n* = 11      age of onset: 3--45 yr; chronic EBV viremia (100%); EBV-induced lymphoproliferation (not HLH); EBV^+^ B lymphoma (Burkitt's/Hodgkin's/ DLBCL; 70%); CD4^+^ T cell lymphopenia (∼50%); splenomegaly; progressive hypogammaglobulinemia (\>50%)                                                         EBV; VZV, HSV, CMV, KSHV, molluscum contagiosum               ∼30% mortality; poor outcomes after HSCT                                                                                           [@bib61]; [@bib19]; [@bib30]; [@bib88]; Brigida et al., 2016
  *CD27*; *n* = 17               age of onset: 1--22 yr; EBV viremia (∼90%); severe HLH (∼25%); EBV-induced lymphoproliferation (∼50%); EBV^+^ B lymphoma (Hodgkin's, DLBCL; ∼50%); hypogammaglobulinemia (∼70%)                                                                                                                       EBV; VZV, CMV (\<15%); recurrent bacterial/viral infections   ∼30% mortality; 3/3 patients successfully treated with HSCT                                                                        [@bib125]; [@bib99]; [@bib3]
  *CD70*; *n* = 5                age of onset: 1--5 yr; EBV viremia (100%); EBV-lymphoproliferation (80%); EBV^+^ B lymphoma (Hodgkin's; 80%); hypogammaglobulinemia (60--80%)                                                                                                                                                         EBV; VZV, CMV (50%); recurrent bacterial/viral infections     all patients currently alive                                                                                                       [@bib1]; [@bib51]
  *NFKB1*; *n* = 2               age of onset: 14--15 yr; EBV viremia; lymphoproliferation, hepatosplenomegaly; hypogammaglobulinemia                                                                                                                                                                                                  EBV; recurrent viral/ bacterial/fungal infections             alive and awaiting HSCT                                                                                                            [@bib14]; [@bib103]
  *RASGRP1*; *n* = 1             age of onset: 12 yr; EBV^+^ B lymphoma; CD4^+^ T cell lymphopenia                                                                                                                                                                                                                                     EBV; recurrent bacterial/viral infections                     successful HSCT                                                                                                                    [@bib100]

Abbreviations used: DLBCL, diffuse large B cell lymphoma; FIM, fulminant IM; HHV6, human herpesvirus 6; KSHV, Kaposi's sarcoma herpes virus; NHL, non-Hodgkin's lymphoma.

X-linked lymphoproliferative disease (XLP) 1: mutations in *SH2D1A* {#s07}
-------------------------------------------------------------------

XLP-1 was initially reported in 1974--1975 in 13 otherwise healthy males from three unrelated families who developed an often-fatal immune-deficient condition precipitated by EBV infection ([@bib7]; [@bib91]; [@bib92]). Remarkably, XLP-1 patients have normal responses to other childhood viruses including other herpesviruses (HSV, varicella zoster virus \[VZV\], and CMV; [@bib27]; [@bib80]). This established that individuals with XLP-1 are uniquely sensitive to diseases caused by EBV, which otherwise runs a fairly benign course in most healthy individuals.

XLP-1 is caused by mutations in *SH2D1A*, encoding signaling lymphocytic activation molecule (SLAM)--associated protein (SAP). SAP is an SH2 domain--containing intracellular adaptor protein that regulates signaling downstream of the SLAM family of surface receptors expressed on hematopoietic cells ([@bib25]; [@bib73]; [@bib102]). Analyses of \>150 patients revealed that the most common clinical features of XLP-1 are EBV-induced fulminant IM/HLH (∼45--70%), B cell lymphoma (∼25%), and hypogammaglobulinemia (∼50%). Lymphoma and Ab defects occur equally in EBV-naive and EBV^+^ XLP patients ([@bib115]; [@bib11]; [@bib79]). The current survival rate in XLP-1 is 71.4%, a marked improvement over the 25% reported in the 1980s ([Table 1](#tbl1){ref-type="table"}; [@bib11]; [@bib79]). This reflects improved detection of affected individuals and patient management in the time since the molecular lesion underlying XLP-1 was identified in 1998. It is important to note that XLP-1 is unique among all currently identified PIDs, as it is the only condition where affected individuals are susceptible to severe disease caused by only EBV infection and not other pathogens. This indicated that SLAM/SAP signaling is critical for protective immunity against EBV infection, but it is redundant for immunity against other infections.

XLP-2: mutations in *XIAP* {#s08}
--------------------------

In 2006, [@bib95] reported 12 males presenting with EBV-induced HLH. These individuals had inactivating mutations in *XIAP*, encoding X-linked inhibitor of apoptosis ([@bib95]). The commonality of EBV-induced disease caused by mutations in *SH2D1A* and *XIAP* (affecting ∼60% of cases and triggering HLH in \>80% of cases) led to the naming of these conditions as XLP-1 and XLP-2 ([@bib33]; [@bib79]). Over the past decade, \>100 patients with XIAP deficiency have been identified, and their detailed clinical descriptions have clearly revealed marked differences in disease pathogenesis, severity, and outcomes for XLP-1 and XLP-2. Thus, splenomegaly, cytopenias, fever, recurrent HLH, and inflammatory bowel disease are common in XIAP but not SAP deficiency. Unlike XLP-1, B lymphoma rarely occurs in XIAP deficiency, and when hypogammaglobulinemia is noted in XLP-2, it is usually transient ([@bib33]; [@bib67]; [@bib79]; [@bib111]; [@bib2]). Mortality caused by XIAP deficiency is ∼40%, with approximately one third of deaths resulting from HLH ([@bib67]; [@bib79]). However, a study of patients identified since 2010 indicated that \>95% of patients were alive ([@bib111]), suggesting that, like XLP-1, survival has greatly improved since the discovery of the molecular lesion causing this condition ([Table 1](#tbl1){ref-type="table"}).

IL-2--inducible T cell kinase (ITK) deficiency {#s09}
----------------------------------------------

*ITK* encodes ITK, a member of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of nonreceptor kinases that is expressed by hematopoietic cells involved in proximal TCR signaling. By regulating PLCγ1 phosphorylation, ITK coordinates T cell activation and function ([@bib93]). 13 individuals from eight unrelated families have been identified with loss-of-function biallelic mutations in *ITK*, 12 of whom presented with EBV viremia, EBV-induced lymphoproliferation that frequently developed into lymphoma, CD4^+^ T cell lymphopenia, hepatosplenomegaly, and progressive hypogammaglobulinemia ([@bib49]; [@bib112]; [@bib62]; [@bib66]; [@bib36]; [@bib8]; [@bib24]; [@bib17]). Interestingly, one ITK-deficient patient was identified who presented at the age of 6 yr with recurrent respiratory tract infections, CD4^+^ T cell lymphopenia, and progressive hypogammaglobulinemia but remained EBV naive until 17 yr of age ([@bib104]). This infers that CD4^+^ T lymphopenia and hypogammaglobulinemia occurs in ITK deficiency independently of EBV infection. Of the 13 reported ITK-deficient patients, eight died, whereas two of three survived hematopoietic stem cell transplantation (HSCT; [Table 1](#tbl1){ref-type="table"}; [@bib49]; [@bib112]; [@bib62]; [@bib66]; [@bib36]; [@bib8]; [@bib24]; [@bib17]).

X-MEN disease: *MAGT1* mutations {#s10}
--------------------------------

A syndrome of chronic EBV viremia, EBV^+^ B lymphoma, and CD4^+^ T cell lymphopenia in seven males was first reported in 2011 ([@bib61]). Because of the clinical features of this condition, it was named X-MEN disease (X-linked immunodeficiency with magnesium defect EBV and neoplasia). Some individuals also presented with recurrent infections with pathogens other than EBV (e.g., HSV and VZV). Molecular studies identified mutations in *MAGT1*, encoding a ubiquitously expressed magnesium transporter controlling basal levels of intracellular Mg^2+^, in all affected individuals ([@bib61]). Since the initial identification of X-MEN patients, four additional individuals have been reported ([@bib30]; [@bib88]; [@bib16]). All 11 patients experienced extremely high levels of EBV viremia, with EBV-induced B cell lymphoproliferation or malignancy occurring in 70% of cases ([@bib61]; [@bib30]; [@bib88]). Three patients died of complications of EBV infection ([Table 1](#tbl1){ref-type="table"}). The discovery of mutations in *MAGT1* revealed an unappreciated and nonredundant role for magnesium as a second messenger, upstream of Ca^2+^, in TCR-mediated activation and immunity against EBV-induced infectious disease and malignancy.

CD27 and CD70 deficiency {#s11}
------------------------

In 2012 and 2013, two papers reported 10 patients from four kindreds presenting with a combined immunodeficiency characterized by EBV viremia, lymphoproliferative disease, HLH, EBV^+^ B cell lymphoma, hypogammaglobulinemia, and impaired Ab responses ([@bib125]; [@bib99]). Molecular analysis revealed homozygous mutations in *CD27* ([@bib125]; [@bib99]), a TNFR superfamily member expressed by naive and central memory T cells, germinal center and memory B cells, plasma cells, and some NK cells ([@bib40]; [@bib60]; [@bib52]; [@bib12]; [@bib127]; [@bib117]). A total of 16 patients from eight unrelated families have now been reported with biallelic loss-of-function mutations in *CD27* ([@bib125]; [@bib99]; [@bib3]). One individual with a heterozygous mutation has also been identified ([@bib3]). As heterozygous parents and siblings of patients with homozygous *CD27* mutations are unaffected, this patient probably has an unidentified mutation on the other *CD27* allele. EBV-induced disease was evident in 88% (15/17) of patients, manifesting as HLH (23.5%), lymphoproliferative disease (53%), and B cell lymphoma (47%), and was fatal in 30% of cases ([Table 1](#tbl1){ref-type="table"}). A few CD27-deficient patients were infected with other herpesviruses (CMV and VZV), and several had recurrent bacterial infections ([@bib125]; [@bib99]; [@bib3]), possibly caused by humoral immune defects, as engaging CD27 promotes human B cell differentiation ([@bib12]; [@bib117]). Thus, CD27 deficiency is a PID characterized by extreme susceptibility to EBV infection and impaired Ab responses.

The counter-structure of CD27 is CD70 ([@bib60]; [@bib12]). CD70 is largely absent from naive or resting leukocytes but is rapidly induced after activation of B cells, myeloid cells, and to a lesser extent T cells ([@bib46]; [@bib120], [@bib121]; [@bib60]; [@bib12]; [@bib51]). Thus, CD70 is predominantly expressed by activated APCs, with highest levels on B cells. Recently, two groups identified five individuals from three unrelated families with homozygous mutations in *CD70*, affecting either expression of CD70 or its ability to bind CD27 ([@bib1]; [@bib51]). The clinical features of CD70 deficiency resembled those of CD27 deficiency, with all patients experiencing EBV viremia and most developing EBV-associated lymphoproliferation or B cell malignancy, hypogammaglobulinemia, and impaired Ag-specific Ab responses; infection with other herpesviruses also occurred in a few patients. However, unlike CD27 deficiency, all patients with CD70 deficiency are currently alive ([Table 1](#tbl1){ref-type="table"}; [@bib1]; [@bib51]), suggesting mutations in *CD27* cause more severe disease than those in *CD70*. Although this seems paradoxical, as CD70 is the only ligand for CD27 ([@bib60]; [@bib12]), this may reflect a ligand-independent function of CD27. Other members of the TNFR superfamily, such as CD95, TNF-RI, CD40, and TACI (transmembrane activator and CAML interactor), form homotrimers independently of interacting with cognate ligands ([@bib20]; [@bib107]; [@bib35]). Thus, preassembled trimers may provide a qualitatively different signal from that initiated by ligand-induced receptor multimerization ([@bib37]). Although this has not been formally established, one possibility is that, in the absence of CD70, only ligand-dependent signals are compromised, whereas in the absence of CD27, both ligand-dependent and -independent signals are impaired, thus resulting in a more severe phenotype. The identification of additional CD70-deficient patients will facilitate investigating this hypothesis.

Mechanisms underlying susceptibility to EBV-induced disease in PIDs {#s12}
===================================================================

Analyses of defects in these PID patients have not only revealed mechanisms of disease pathogenesis, but also have defined unique requirements for host defense against EBV and identified pathways that could be targeted to improve anti-EBV immunity in immunocompromised hosts.

XLP-1 {#s13}
-----

Early studies of XLP-1 reported defects in NK cell cytotoxicity ([@bib114]). Subsequent studies revealed that the ability of SAP-associating receptors 2B4 and NTB-A to activate NK cell cytotoxicity was abolished in the absence of SAP ([@bib71]; [@bib85]; [@bib118]; [@bib13]). Activation of Ag-specific CD8^+^ T cells by B cells, but not other APCs (monocytes, DCs, and fibroblasts), was also impaired by SAP deficiency ([@bib32]; [@bib48]; [@bib81]). Consistent with these findings, SAP-deficient T and NK cells exhibited intact responses when activated through SAP-independent receptors ([@bib71]; [@bib85]; [@bib118]; [@bib13]; [@bib32]). Thus, successful engagement of CD8^+^ T cells by cognate B cells requires interactions between SLAM receptors and SAP-dependent signaling in responding CD8^+^ T cells.

As EBV is a B cell tropic--virus, these findings explain the (a) selectivity of XLP-1 patients to infection with EBV but not human herpesviruses with other cell tropisms, (b) increased incidence of B cell lymphoma in XLP-1, and (c) EBV independence of lymphoma development in these patients; i.e., SAP-deficient, lymphoma-specific CD8^+^ T cells would be unresponsive to activating signals provided by B cell lymphomas via SLAM/SAP complexes. Interestingly, ligands of 2B4 (CD48) and NTB-A (NTB-A itself) are highly expressed on EBV-infected B cells ([@bib123]; [@bib85]). This suggests that EBV-induced up-regulation of CD48 and NTB-A on B cells acts as a signal to activate NK cells as a first line of defense against viral infection and, subsequently, functions to activate EBV-specific CD8^+^ T cells.

SAP-deficient T cells are also resistant to reactivation-induced cell death, a process considered to regulate T cell contraction during responses to specific Ags ([@bib109]). Enhanced survival of SAP-deficient cells was NTB-A dependent and resulted from impaired induction of proapoptotic Bim and Fas ligand ([@bib109]). SAP-deficient human CD8^+^ T cells also exhibited enhanced proliferation to polyclonal stimulation relative to SAP^+^ CD8^+^ T cells ([@bib82]). Sustained proliferation and persistence of highly activated CD8^+^ T cells may contribute to HLH in XLP-1 ([@bib33]; [@bib67]).

XLP-2 {#s14}
-----

In contrast to XLP-1, functional responses of cytolytic lymphocytes from XIAP-deficient patients are normal ([@bib95]; [@bib2]). XIAP prevents apoptosis by binding and inactivating caspases ([@bib2]). Thus, T cells with *XIAP* mutations exhibit increased death after TCR stimulation ([@bib95]; [@bib33]; [@bib111]). It is possible that activation-induced loss of effector T cells compromises effective control of viral infection, thereby predisposing XIAP-deficient individuals to EBV infection and HLH. However, the exact mechanisms underlying disease in XIAP deficiency remain unclear, particularly as SAP deficiency protects T cells from restimulation-induced cell death allowing prolonged proliferation ([@bib109]; [@bib82]), with HLH characterized by dysregulated proliferation of cytotoxic lymphocytes ([@bib33]; [@bib67]).

X-MEN {#s15}
-----

*MAGT1* mutations abrogate TCR-mediated PLCγ1 activation and subsequent Ca^2+^ flux, thereby impairing T cell function ([@bib61]). However, it was unclear how a global defect in TCR-induced activation would render affected individuals susceptible to EBV infection. Insight into this came from the finding that MAGT1-deficient NK and CD8^+^ T cells failed to express NKG2D ([@bib19]; [@bib30]; [@bib88]; [@bib16]), a C-type lectin that potently activates effector function of cytotoxic lymphocytes ([@bib58]). Thus, despite individuals with *MAGT1* mutations being able to generate EBV-specific CD8^+^ T cells, these cells could not kill autologous, EBV-transformed B cells ([@bib19]).

The functional requirement for NKG2D on MAGT1-deficient NK and CD8^+^ T cells was elegantly demonstrated by the ability to restore both expression of NKG2D and NKG2D-dependent cytotoxicity by in vitro treatment with magnesium ([@bib19]). Remarkably, in vivo administration of magnesium to X-MEN patients restored NKG2D expression on CD8^+^ T cells, and this correlated with reductions in proportions of EBV-infected B cells ([@bib19]). Thus, recognition of EBV-infected B cells by NK and CD8^+^ T cells critically depends on interactions between NKG2D on cytolytic lymphocytes and its cognate ligands on EBV-B cells.

CD27/CD70 deficiency {#s16}
--------------------

Analysis of CD8^+^ T cells from patients with *CD70* mutations also revealed an impaired ability to kill autologous EBV-infected B cells. Interestingly, CD27/CD70 interactions were critical for initial priming and expansion of EBV-specific CD8^+^ T cells, rather than activating cytotoxic function ([@bib1]; [@bib51]). Importantly, cytotoxicity of effector CD8^+^ T cells from CD70-deficient individuals against autologous EBV-B cells could be greatly improved by restoring CD70 expression on the target B cells ([@bib51]). Thus, consistent with CD70 being more prominently expressed on APCs than on T cells, CD27 delivers the activating signal to T cells for their effector function, with CD70 on APCs---predominantly B cells---acting as the ligand in this interaction ([@bib60]; [@bib12]; [@bib51]). Notably, memory and EBV-specific CD8^+^ T cells from CD70-deficient individuals failed to up-regulate expression of NKG2D and 2B4 ([@bib1]). Thus, mutations in *CD70*, and by inference *CD27*, compromise the ability of CD8^+^ T cells to be activated by EBV-infected B cells by at least two pathways---directly via CD27 and indirectly by crippling 2B4- and NKG2D-induced cytotoxicity ([Fig. 2](#fig2){ref-type="fig"}).

![**Signaling pathways responsible for generating cell-mediated EBV-specific immunity.** The scheme highlights the key cell surface receptor-induced signaling pathways that, when mutated, manifest as PIDs characterized by increased susceptibility to EBV-induced disease. Genes found to be mutated in these conditions (SAP/*SH12D1A*, *MAGT1*, *ITK*, *CD27*, *CD70*, *NFKB1*, and *RASGRP1*) are highlighted by red boxes. XIAP is not included here, as the mechanism by which mutations in *XIAP* cause disease remains unknown.](JEM_20161846_Fig2){#fig2}

Converging mechanisms underlying EBV susceptibility in genetically distinct PIDs {#s17}
================================================================================

There are several points of intersection in the molecular pathogenesis of severe EBV-induced disease caused by mutations in *SH2D1A*, *ITK*, *MAGT1*, and *CD27*/*CD70*, despite these molecules functioning in distinct signaling pathways ([Fig. 2](#fig2){ref-type="fig"}). First, phosphorylation of PLCγ1, a substrate of ITK, induces the intracellular Ca^2+^ flux necessary for TCR-mediated T cell activation ([@bib93]; [@bib36]). Mutations in *ITK* or *MAGT1* largely abolished TCR-induced PLCγ1 activation ([@bib93]; [@bib61]; [@bib62]; [@bib16]). Thus, ITK can function downstream of the TCR and MAGT1 signaling pathways, thereby explaining common clinical outcomes of mutations in *MAGT1* or *ITK* ([Table 1](#tbl1){ref-type="table"}).

Second, a key feature of X-MEN patients is a lack of NKG2D expression on cytolytic cells, which compromises their ability to lyse EBV-infected B cells ([@bib19]; [@bib30]; [@bib88]). In contrast, SAP is required for 2B4- and NTB-A--mediated activation of NK and T cells by B cells ([@bib48]; [@bib81]). Thus, reduced expression of NKG2D and 2B4 on CD8^+^ T cells from CD70-deficient individuals likely contributes to their impaired responsiveness to EBV-infected B cells, akin to that observed for MAGT1- and SAP-deficient CD8^+^ T cells in X-MEN disease and XLP-1, respectively ([Fig. 2](#fig2){ref-type="fig"}). Third, co-engagement of 2B4 and NKG2D on human NK cells yields a greater response than engaging either receptor alone ([Fig. 2](#fig2){ref-type="fig"}; [@bib57]). Such synergy between 2B4 and NKG2D potentially explains previous puzzling observations of why an inability to signal through 2B4 in the absence of SAP could not be compensated by other pathways, including NKG2D, and vice versa. It is likely that co-signaling through NKG2D and SLAM receptors is required to induce activation of Ag-specific CD8^+^ T cells and acquisition of cytotoxic function to lyse EBV-infected B cells. Fourth, it is striking that expression of ligands of CD27, 2B4, NTB-A, and NKG2D are greatest on EBV-infected B cells ([@bib123]; [@bib60]; [@bib13]; [@bib58]; [@bib51]). These observations further underscore the concept that individuals with mutations in *SH2D1A*, *MAGT1*, *CD27*/*CD70*, or *ITK* are particularly susceptible to disease caused by EBV simply because of the B cell tropism of EBV and subsequent compromised ability of CD8^+^ T cells from these individuals to be optimally activated by Ag-presenting B cells ([Fig. 2](#fig2){ref-type="fig"}).

Identifying these points of overlap and cooperativity in signaling pathways defective in PIDs arising from mutations in *SH2D1A*, *ITK*, *MAGT1*, *CD27*, or *CD70* also potentially explains susceptibility to EBV-induced disease innovel PIDs. Two unrelated patients with lymphoproliferation, severe EBV viremia, and heterozygous mutations in *NFKB1* ([@bib14]; [@bib103]) and one patient with homozygous mutations in *RASGRP1* with a combined immunodeficiency, CD4^+^ T cell lymphopenia, and EBV^+^ B cell lymphoma ([@bib100]) were recently identified ([Table 1](#tbl1){ref-type="table"}). NKG2D, 2B4, or CD27 can all activate NF-κB1 ([@bib60]; [@bib57]), and co-engagement of NKG2D and 2B4 results in a robust NF-κB1 response ([@bib57]). RasGRP1 is a guanine nucleotide exchange factor activated by diacylglycerol, a second messenger produced by cleavage of phosphatidylinositol-4,5-bisphosphate by PLCγ1 downstream of ITK ([@bib93]). Thus, these two new genetic etiologies probably cause EBV-induced disease by compromising lymphocyte activation induced via TCR/ITK/PLCγ1 signaling (RasGRP1) or NF-κB1--activating receptors (2B4, NKG2D, and CD27; [Fig. 2](#fig2){ref-type="fig"}). In light of these findings, it will be important to determine whether engagement of these receptors can activate other signaling pathways implicated in EBV-susceptible PIDs, such as Ca^2+^ or Mg^2+^ flux or PLCγ1 activation.

The relative importance of innate versus adaptive immune cells in responses against EBV infection {#s18}
=================================================================================================

Detailed studies of PIDs allow identification of redundant and nonredundant roles of particular cell types in anti-EBV immunity. A common feature of individuals with mutations in *SH2D1A*, *XIAP*, *ITK*, and *CD27* is a paucity of NKT cells ([@bib74]; [@bib87]; [@bib95]; [@bib49]; [@bib112]; [@bib99]; [@bib36]; [@bib104]). This, together with additional experimental evidence ([@bib23]), suggests that NKT cells may play a fundamental role in anti-EBV immunity. However, although this is a tempting hypothesis, it has important caveats. First, assessment of EBV-naive XIAP-deficient patients revealed normal frequencies of NKT cells, with studies indicating that the loss of NKT cells in these individuals was secondary to EBV infection ([@bib33]; [@bib67]; [@bib111]). Thus, although a diminution in the frequency of NKT cells after EBV infection may compromise host defense, EBV-induced disease in XLP-2 does not result per se from a primary absence of NKT cells. Second, individuals with mutations in *RORC* completely lack NKT cells and are susceptible to infection with mycobacteria and candida but not EBV ([@bib76]), arguing against a central role for NKT cells in anti-EBV immunity. Despite these observations, it cannot be entirely ruled out that a deficiency of NKT cells may contribute to disease pathogenesis in these PIDs. Indeed, NKT cells are polyfunctional and can influence the behavior of numerous cell types, including DCs, granulocytes, macrophages, B cells, and T cells ([@bib15]). Thus, it is possible that a lack of NKT cell--mediated activation of these immune cells underlies some of the additional clinical features typical of PIDs resulting from *SH2D1A*, *XIAP*, *ITK*, or *CD27* mutations.

Similar arguments have been made for essential roles of NK cells in protection against EBV. Many examples exist of PIDs characterized by compromised development or function of NK cells and overwhelming infections with viruses, including EBV ([@bib77]), consistent with a role for NK cells in EBV immunity ([@bib21], [@bib22]; [@bib77]). However, most PIDs characterized by defects in NK cell development or function usually have defects in other cell lineages, such as T cells ([@bib77]; [@bib80]). Thus, susceptibility to infection in these settings probably results from the combined effect of impaired T and NK cell--mediated immunity. Indeed, a recent study reported that the T cell, but not NK cell, compartment is restored in individuals with SCID because of mutations in *IL2RG* or *JAK3* after HSCT, thus rendering them NK cell deficient ([@bib126]). Remarkably, NK cell deficiency in these transplanted individuals did not result in any adverse clinical phenotype with respect to increased frequency of pathogen infection, including with herpesviruses ([@bib126]). These data suggest T cells are predominantly responsible for long-term protection against EBV infection, and NK cells play a complementary, rather than exclusive, role in host defense. This is consistent with the finding that, in XLP-1 patients, somatic reversion of *SH2D1A*, resulting in expression of functional SAP, is largely restricted to memory CD8^+^ T cells and is infrequently detected in NK cells ([@bib82]), inferring that the pressure exerted on the immune system by EBV preferentially drives responses by CD8^+^ T cells. A predominant role of CD8^+^ T cells in host defense against EBV is also evident by a lack of severe EBV-induced disease in individuals with mutations in *RFXANK*, which dramatically reduces expression of MHC class II causing severe CD4^+^ T cell lymphopenia ([@bib78]).

Cellular therapy for treatment of EBV-induced disease {#s19}
=====================================================

Studies of patients with EBV-associated pathologies, including those with specific PIDs, have demonstrated the requirement for intact cellular immunity in controlling EBV. This has facilitated the development of treatment protocols using EBV-targeted cellular therapy.

PTLD {#s20}
----

Allogeneic HSCT and solid organ transplantation (SOT) can treat a myriad of human conditions. However, the success of these treatments can be curtailed by susceptibility of transplant recipients to viral infections after immunosuppression ([@bib69]). Recipients are particularly vulnerable to complications associated with primary EBV infection or reactivation of latent infection, either arising naturally or transmitted from the donor graft ([@bib38]). During immunosuppression, surveillance of EBV-infected B cells is compromised resulting in EBV viremia and uncontrolled lymphoproliferation. This manifests as PTLD, a potentially life-threatening complication in ∼1--30% of transplant recipients ([@bib96], [@bib97]; [@bib65]; [@bib39]; [@bib72]; [@bib124]).

EBV-induced PTLD can be treated by combination chemotherapy ([@bib43]) or B cell depletion ([@bib54]; [@bib124]). However, because most PTLD lesions are EBV^+^ ([@bib9]), cellular immunotherapy targeting EBV Ags expressed by infected B cells has become an attractive strategy for prophylaxis and treatment ([Fig. 3](#fig3){ref-type="fig"}). Indeed, \>75% of PTLD patients undergoing adoptive cellular therapy using EBV-specific CD8^+^ T cells achieved complete remission ([@bib44], [@bib45]; [@bib39]; [@bib31]) including some with rituximab-resistant disease ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}; [@bib28]). Furthermore, when administered prophylactically, none of the patients developed PTLD compared with 11.5% of HSCT recipients not receiving T cell immunotherapy ([@bib45]). Thus, adoptive cell therapy is a viable means of controlling EBV-driven lymphoproliferation in immunosuppressed individuals.

![**Schematic representation of the generation of EBV-specific T cells to treat EBV-associated disease.** PBMCs are isolated from donors and stimulated using different approaches to generate EBV-specific T cells, which are then infused into patients after conditioning or immunosuppressive therapy.](JEM_20161846_Fig3){#fig3}

###### Prophylaxis for EBV-induced PTLD (or treatment for increased EBV DNA levels)

  EBV-specific T cell activator               T cell source              Prophylaxis for   EBV-specific pathology                                    References
  ------------------------------------------- -------------------------- ----------------- --------------------------------------------------------- ----------------------------------------
  LCL                                         Transplant donor derived   Post-HSCT PTLD    0/101 developed PTLD                                      [@bib96], [@bib97]; [@bib44], [@bib45]
                                                                                           5/6 exhibited a decrease in EBV DNA                       [@bib39]
                                                                                           1/4 decrease in EBV DNA                                   [@bib28]
                                              Allogeneic                 Post-HSCT PTLD    0/1 showed evidence of viral activation (EBV, CMV, ADV)   [@bib70]
  DCs + LCLs transduced with ADV              Transplant donor derived   Post-HSCT PTLD    0/1 showed evidence of viral activation (EBV, CMV, ADV)   
  DCs + LCLs transduced with ADV + CMV pp65   Transplant donor derived   Post-HSCT PTLD    0/2 showed evidence of viral activation (EBV, CMV, ADV)   
                                              Allogeneic                 Post-HSCT PTLD    0/3 showed evidence of viral activation (EBV, CMV, ADV)   
  Viral Ags from EBV, CMV, ADV                Transplant donor derived   Post-HSCT PTLD    0/2 showed evidence of viral activation (EBV, CMV, ADV)   

Abbreviations used: ADV, adenovirus.

###### Treatment for EBV-associated malignancies

  EBV-specific T cell activator                               T cell source               Disease                                                  CR, PR, remission, or disease free   References
  ----------------------------------------------------------- --------------------------- -------------------------------------------------------- ------------------------------------ ----------------------------------------
  LCL                                                         Transplant donor derived    Post-HSCT PTLD                                           11/13                                [@bib96], [@bib97]; [@bib44], [@bib45]
                                                                                                                                                   10/14                                [@bib31]
                                                                                                                                                   1/1                                  [@bib65]
                                                                                                                                                   3/4                                  [@bib28]
                                                              Allogeneic                  Post-HSCT PTLD                                           4/5                                  [@bib31]
                                                                                          Post-HSCT viremia or EBV-LPD                             9/10                                 [@bib70]
                                                                                          Post-SOT PTLD                                            15/31                                [@bib41]
                                                              Autologous                  Post-SOT PTLD                                            1/1                                  [@bib53]
  Viral Ags from EBV, CMV, and ADV                            Transplant donor derived    Post-HSCT PTLD                                           2/2                                  [@bib70]
                                                              Allogeneic                  Post-HSCT viremia or EBV-LPD                             1/2                                  [@bib70]
  APCs transduced with ADV vector encoding LMP1 and/or LMP2   Autologous or third party   Active EBV^+^ lymphoma; EBV^+^ lymphoma (in remission)   13/21; 27/29                         [@bib10]

Abbreviations used: ADV, adenovirus; CR, complete response; LPD, lymphoproliferative disease; PR, partial response.

Combining HSCT and adoptive cellular therapy in PIDs {#s21}
----------------------------------------------------

HSCT can cure ∼70--90% of patients with PIDs ([@bib108]). However, HSCT often fails to provide rapid protection against viral infections ([@bib69]). For this reason, HSCT has been combined with adoptive cellular therapy to enhance immune-mediated control of infection by EBV and other viruses. A retrospective study of 36 high-risk PID patients who received prophylactic virus-specific T cells to treat viral infections either before or after HSCT found that 81% remained free of EBV, CMV, and adenovirus. Although the remaining 19% exhibited reactivation of EBV or CMV, their infection resolved within 2 mo of onset. Overall, 76% of the patients treated therapeutically for active EBV infection exhibited a complete or partial response to cellular therapy ([Table 2](#tbl2){ref-type="table"}[@bib70]).

SOT {#s22}
---

Outcomes of SOT patients receiving autologous EBV-specific T cells to treat high EBV loads or active PTLD have been promising, with \>50% showing a complete or partial response ([Table 3](#tbl3){ref-type="table"}; [@bib53]; [@bib101]; [@bib41]). The requirement for continued immunosuppression likely reflects the lower response rate compared with HSCT (56% versus 75%, respectively). The demonstration that CD8^+^ T cells specific for latent rather than lytic EBV Ag were necessary for the effective treatment of PTLD ([@bib106]) will aid efficient Ag targeting for the treatment of these patients. Impaired generation of autologous T cells as well as potential alloreactivity as a result of intense immunosuppression and/or seronegativity of the recipient represent major drawbacks in the treatment of SOT recipients ([@bib53]; [@bib101]). However, the continuing evolution of the field, most prominently the availability of banked allogeneic T cell products, will potentially circumvent these issues.

EBV^+^ B cell malignancies {#s23}
--------------------------

Adoptive cellular therapy has also been trialled in a subset of patients with EBV^+^ B cell lymphoma including Hodgkin's lymphoma. Here, 56% of patients infused with EBV-specific CD8^+^ T cells were in remission up to 4 yr after treatment, and a further 26% showed clinical responses for relapsed or refractory disease ([Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}; [@bib10]). These outcomes are particularly promising because a subset of EBV-PID patients present with or develop EBV^+^ B lymphomas during the clinical course of their disease (∼50--80%; [Table 1](#tbl1){ref-type="table"})

Developments aimed at broadening the EBV Ags that are targeted by CD8^+^ T cells, streamlining the manufacture, and improving strategies to expand EBV-specific T cells will further improve the efficacy of adoptive cellular therapy to control EBV-induced disease. It is likely that adoptive cellular therapy will be used as combinatorial treatments for EBV-associated disease. Ongoing development of an EBV vaccine will further improve our ability to combat EBV-induced disease.

Conclusions and perspectives {#s24}
============================

EBV infection is a remarkable example of host--pathogen evolution as the majority of the adult population has been exposed to EBV, yet only a minor proportion develops severe disease. Consequently, EBV infection can manifest in a variety of ways: asymptomatic/mild infection, IM, HLH, or a variety of malignancies. These clinical features are most prominent in immunocompromised individuals resulting from coincident infections, iatrogenic therapies, or gene mutations. Studies of monogenic immunodeficient patients with a predisposition to EBV-induced disease have been extremely instructive in revealing the cellular, biochemical, and molecular requirements for robust immunity against EBV infection. These analyses have also highlighted redundancies in immune control of EBV. Exploiting such findings, combined with further investigation into the etiology of EBV infection, immunity, and disease, will pave the way for ongoing development of improved methodologies for treating EBV-induced disease, such as adoptive cellular therapy, and the realization of a successful prophylactic vaccine. The study of EBV-induced disease in PIDs is a stark illustration of how insights from basic and clinical investigations of rare individuals can yield substantial outcomes for the treatment of disease resulting from a persistent virus in the general population.
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